Related Experiment Video
Updated: May 14, 2026
09:44
Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Rationally designed multi-targeted agents against neurodegenerative diseases
W J Geldenhuys1, C J Van der Schyf
1Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Current Medicinal Chemistry
|February 16, 2013
Summary
Multi-targeted designed drugs (MTDDs) show promise for neurodegenerative diseases by targeting multiple pathways. Chemical scaffolds like polycyclic cages, thiazolidinediones, stilbenes, and xanthines are key to developing these neuroprotective agents.
Area of Science:
- Neuroscience
- Medicinal Chemistry
- Pharmacology
Background:
- Neurodegenerative diseases involve complex pathoetiological pathways leading to neuronal cell death.
- Current treatments often target single pathways, limiting efficacy.
- Multi-targeted designed drugs (MTDDs) offer a promising strategy for neuroprotection and disease modification.
Purpose of the Study:
- To review the application of chemical scaffolds in developing MTDDs for neurodegenerative diseases.
- To highlight specific scaffolds and their mechanisms of action in preclinical models.
Main Methods:
- Review of literature on MTDDs for neurodegeneration.
- Analysis of chemical scaffolds including polycyclic cage compounds, thiazolidinediones, and stilbenes.
- Examination of drug design strategies, such as moiety amalgamation and natural product templates.
Main Results:
- Polycyclic cage compounds serve as scaffolds for calcium channel blockers, NMDA receptor antagonists, and sigma-receptor ligands.
- Thiazolidinedione derivatives target mitochondrial function via mitoNEET.
- Ladostigil combines acetylcholinesterase and MAO-B inhibition.
- Stilbene derivatives reduce beta-amyloid aggregation and ROS, and act as MAO inhibitors.
- Xanthine derivatives show neuroprotection in Parkinson's disease via adenosine A2A antagonism and MAO-B inhibition.
Conclusions:
- Chemical scaffolds are crucial for designing effective MTDDs in neurodegeneration.
- Diverse scaffolds offer multiple mechanisms to combat neurodegenerative processes.
- MTDDs represent a significant advancement in the preclinical development of neuroprotective therapies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...